Sorafenib

Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate

Retrieved on: 
Wednesday, March 27, 2024
Cell proliferation, Apoptosis, Survival, Patent, Colorectal cancer, T-cell lymphoma, Neoplasm, Guard cell, Mitochondrion, IC50, Cisplatin, HK2, Sorafenib

(Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it has received a Notice of Allowance from the Japanese Patent Office for the composition and methods of use for its VDA-1275 drug candidate, which has shown multiple promising effects in preclinical studies.

Key Points: 
  • (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it has received a Notice of Allowance from the Japanese Patent Office for the composition and methods of use for its VDA-1275 drug candidate, which has shown multiple promising effects in preclinical studies.
  • “Receiving this notice from the Japanese authorities adds to our excitement about VDA-1275, Vidac’s next and powerful anti-cancer drug candidate.
  • Cancer cells overexpress HK2, which catalyzes the first step of the glucose metabolism necessary to fuel tumor growth.
  • Clinical data for Vidac’s first-generation metabolic checkpoint modulator candidates have shown powerful effects in halting cancer cell proliferation and restoring immune-sensitivity and apoptosis.

Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, HCC, Bristol Myers Squibb, OS, BMY, TKI, Ipilimumab, Patient, Checkmate, Sorafenib, Immunotherapy, Survival, Nivolumab, Pharmaceutical industry

The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib.

Key Points: 
  • The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib.
  • The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals identified.
  • “Advanced stage liver cancer patients remain in need of additional treatment options that may help improve survival,” said Dana Walker, M.D., M.S.C.E., vice president, global program lead, gastrointestinal and genitourinary cancers, Bristol Myers Squibb.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -9DW clinical trial.

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Tuesday, February 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Tuesday, February 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

Retrieved on: 
Tuesday, February 6, 2024
OS, Vanderbilt-Ingram Cancer Center, VEGFR, Survival, IO, TKI, Renal cell carcinoma, Division, RCC, MD, PFS, Safety, Patient, Progression-free survival, Sorafenib, Arm, Disease, ITT, Assistant, Oncology, LG Chem, Doctor of Philosophy, Pharmaceutical industry

The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.

Key Points: 
  • The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.
  • “For patients with relapsed or refractory advanced renal cell carcinoma, long-term progression-free survival is a vital measure of the value of anticancer therapy,” commented Michael Bailey, President and CEO of AVEO Oncology.
  • The trial randomized 350 patients to receive FOTIVDA (1.5 mg once daily) or sorafenib (400 mg twice daily).
  • The intent-to-treat (ITT) population included 175 patients in each arm; the safety population included 173 patients in the FOTIVDA arm and 170 in the sorafenib arm.

Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
Thursday, January 18, 2024
CP, Patient, Therapy, Sorafenib, PD-1, ASCO, Survival, Society, Camrelizumab, Quality of life, Hepatocellular carcinoma, Food, DIH, Hepatotoxicity, FDA, PDUFA, TKI, Moscone Center

ASCO GI will be held Jan. 18-20, 2024, at the Moscone Convention Center (West) in San Francisco, and online.

Key Points: 
  • ASCO GI will be held Jan. 18-20, 2024, at the Moscone Convention Center (West) in San Francisco, and online.
  • Elevar’s poster presentations are:
    Abstract Title: Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
  • The results of this post-hoc analysis may have implications for selection of initial and subsequent therapies for uHCC patients.
  • The FDA assigned Prescription Drug User Fee Act (PDUFA) target action dates in May 2024.

Elevar Therapeutics and Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC

Retrieved on: 
Tuesday, October 17, 2023
Congress, Jiangsu Hengrui Medicine, Food, Hepatocellular carcinoma, Research, Standard of care, BLA, Death, Survival, R, Liver cancer, FDA, ESMO, Therapy, Oncology, Sorafenib, NDA, Regulation of tobacco by the U.S. Food and Drug Administration, European Society for Medical Oncology, PDUFA, Progression-free survival, HCC, Patient, Pharmaceutical industry, Generic drug, Lancet, EU

Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.

Key Points: 
  • Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
  • In May 2023, a new drug application (NDA) for rivoceranib and a biologics license application (BLA) for camrelizumab were submitted to the U.S. Food and Drug Administration (FDA) for the combination of rivoceranib and camrelizumab as a first-line therapy for uHCC.
  • In January 2023, the combination was approved in China as a first-line treatment for uHCC.
  • Camrelizumab plus rivoceranib significantly prolonged overall survival and progression-free survival, and increased overall response rate versus sorafenib, a standard first-line treatment for uHCC.

Jiangsu Hengrui Pharma and Elevar Therapeutics Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC

Retrieved on: 
Tuesday, October 17, 2023
Congress, Food, Hepatocellular carcinoma, Research, BLA, R, FDA, Sorafenib, Therapy, NDA, Regulation of tobacco by the U.S. Food and Drug Administration, Responses to the COVID-19 pandemic in September 2022, PDUFA, Progression-free survival, HCC, Patient, Pharmaceutical industry, Generic drug, Lancet

Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.

Key Points: 
  • Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
  • Rivoceranib, under the name apatinib (brand name: Aitan®), is developed by Hengrui Pharma in China.
  • Elevar and Hengrui Pharma presented CARES-310 study results at the September 2022 ESMO Congress and published them in The Lancet on July 24, 2023.
  • Camrelizumab plus rivoceranib significantly prolonged overall survival and progression-free survival, and increased overall response rate versus sorafenib, a standard first-line treatment for uHCC.

Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million

Retrieved on: 
Thursday, September 28, 2023
Knowledge, SHC, Therapy, MD, Patient, HCC, Sorafenib, Safety, Series, Pharmaceutical industry, Geneo Grissom

PLYMOUTH MEETING, Pa., Sept. 27, 2023 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million. This investment adds Shanghai Healthcare Capital (SHC) to Geneos' investor syndicate. Dr. Jing Bao will join as a board observer, bringing extensive expertise in the pharmaceutical industry and with global clinical trials.

Key Points: 
  • PLYMOUTH MEETING, Pa., Sept. 27, 2023 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million.
  • This investment adds Shanghai Healthcare Capital (SHC) to Geneos' investor syndicate.
  • Dr. Jing Bao will join as a board observer, bringing extensive expertise in the pharmaceutical industry and with global clinical trials.
  • "We are pleased to add SHC to our investor syndicate and Dr. Bao to our team.

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer

Retrieved on: 
Tuesday, August 22, 2023
Vaccine, DNA, Auckland City Hospital, Electroporation, Radiation, Circulating tumor DNA, University, PPM, Chief Justice of Hungary, Aes, Liquid biopsy, Cancer, Hope, Medicine, Doctor of Philosophy, Șaeș, MRD, NeXT, MRI, CD8, Patient, Sorafenib, EP, Immune system, CR, Cancer vaccine, Liver, CRS, Neoplasm, HCC, CMR, PD-1, Oncology, Pembrolizumab, Recurrence, SD, PR, Safety, Biopsy, Pharmaceutical industry, Medical imaging, Geneo Grissom

PLYMOUTH MEETING, Pa., Aug. 22, 2023 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC). Previously, Geneos reported three patients to have achieved a complete response (CR) and a fourth patient to be cancer-free, whose liver and lung lesions shrank to become fully responsive to surgery and radiation (secondary resectability).

Key Points: 
  • Geneos reports today that four additional patients have achieved a complete molecular response (CMR) by ultrasensitive, third-generation, circulating tumor DNA (ctDNA) analysis.
  • By RECIST1.1, three of these four patients are durable partial responses (PR) and one a durable stable disease (SD).
  • By either RECIST1.1 or by ctDNA response, 11 of 32 evaluable have achieved either a complete response, partial response, or complete molecular response.
  • Cancer vaccines based on our DNA vaccine platform are showing complete responses in patients with late-stage, advanced cancer.